Cyient DLM Q4 FY26: Revenue Falls 17%, Order Book Hits ₹2,416 Crore, But Is This EMS Player Quietly Building A Defence Giant?

1. At a Glance

There are some companies that scream growth from rooftops. Then there are companies like Cyient DLM that quietly sit in the corner, assemble missile electronics, aircraft parts, medical equipment and industrial boxes, while investors argue whether this is just another contract manufacturer with a fancy PowerPoint.

At first glance, the numbers look sleepy. FY26 revenue fell 17% to ₹1,261 crore. Q4 revenue fell 13.8% YoY to ₹369 crore. Quarterly PAT fell 27.7% YoY to ₹22.4 crore. The stock is down around 26% over the last year.

But then the strange things start appearing.

Order book is now at a record ₹2,416.6 crore, the highest in 10 quarters. Book-to-bill stayed above 1 in every quarter of FY26. Aerospace is now 39% of Q4 revenue. Defence is still meaningful at 10%. Build-to-Spec or B2S programs are slowly entering the mix and management claims these programs carry better margins and stronger customer stickiness.

This is where the Cyient DLM story becomes interesting.

The market is currently treating the company like a low-growth EMS vendor that got lucky because of one large defence order in FY25. Management, however, is trying to convince investors that Cyient DLM is becoming a design-led electronics platform with deeper participation in the product lifecycle.

That is a very different business.

One version of Cyient DLM is a company that assembles PCBs and cable harnesses and lives on wafer-thin margins.

The other version is a company that gets embedded into aerospace, defence, medical, automotive and industrial product design cycles, wins long-duration contracts, supplies complex box-builds, and becomes too painful for customers to replace.

The difference between those two businesses is enormous.

But there are still red flags.

Working capital days have exploded to 175 days. Inventory days have jumped to 314 days. Cash conversion cycle is now 270 days. Top-5 customer concentration is extremely high. Promoter holding fell sharply from 66.7% to 52.1% after dilution and institutional flows are becoming more volatile.

So what exactly is Cyient DLM becoming?

A future defence-electronics compounder?

Or a fancy electronics assembler that spends more time talking about “transformation” than generating free cash flow?

That is the real debate.

2. Introduction

Cyient DLM operates in a niche corner of manufacturing that most investors barely understand.

This is not your usual mass-market electronics business where factories spit out lakhs of identical products every day.

Cyient DLM works in low-volume, high-mix manufacturing.

In simple language, it makes smaller quantities of highly customized and often mission-critical products.

That means the company cannot just focus on scale. It must focus on reliability, certifications, quality, documentation, traceability, design validation and customer approvals.

If a mobile charger fails, people get annoyed.

If an avionics board fails in an aircraft, people start appearing on news channels.

That is why Cyient DLM works in segments like aerospace, defence, medical technology, industrial systems and rail.

The company manufactures printed circuit board assemblies, cable harnesses, box builds and electromechanical systems used in cockpits, in-flight systems, landing systems and medical equipment.

Its facilities are located in Mysuru, Hyderabad and Bengaluru, with manufacturing area now above 3.5 lakh square feet.

The interesting part is that management is no longer satisfied with being a backend manufacturing vendor.

The company is now trying to move earlier into the design cycle.

Management repeatedly said in the January 2026 concall that Cyient DLM is participating earlier in customer product development cycles. That means instead of just receiving final designs and assembling products, it wants to become part of the engineering process itself.

This is where B2S becomes important.

B2S or Build-to-Spec means the company contributes to the design, engineering and development process. That typically improves margins, creates stronger client relationships and makes it harder for competitors to replace you.

Management said B2S contribution is currently around 6-7% in FY26 and could become double-digit in FY27.

Now ask yourself something.

If Cyient DLM becomes a serious B2S player in aerospace, defence and industrial electronics, should it really trade like a generic EMS company?

That is exactly the puzzle the market is struggling with.

3. Business Model – WTF Do They Even Do?

Cyient DLM is basically the company behind the company.

It makes the complicated electronics and subsystems that other brands eventually sell.

Its product portfolio has four major buckets:

• PCBA or printed circuit board assemblies
• Cable harnesses
• Box builds
• Mechanical and other integrated systems

PCBA remains the biggest business with around 48% revenue share in Q4 FY26.

Box builds contributed 36%, while mechanical and other systems contributed 15%.

This matters because box builds and integrated systems generally carry higher value addition compared to plain PCB assembly.

Industry-wise, aerospace contributed 39% of Q4 FY26 revenue, industrial 28%, defence 10%, medical technology 21% and others 2%.

Geographically, the business is now overwhelmingly export-driven, with 92% of Q4 revenue coming from the rest of the world and only 8% from India.

That is both good and bad.

The good part is that global customers generally bring higher-quality orders, longer contracts and better pricing.

The bad part is that export-heavy businesses become vulnerable to tariffs, currency swings, customer shipment delays and geopolitical nonsense.

Management admitted in Q3 FY26 that tariff uncertainty and customer delays affected shipments. Some customers entered “wait-and-watch mode” because of global trade issues.

But management also claimed these delays were temporary and that shipments were expected to move into Q4.

The company has customers like Honeywell, Thales, ABB, Bharat Electronics and Molbio Diagnostics.

That is a serious customer list.

But there is a concentration problem.

Top-5 customers contribute around 75-80% of revenue.

That means if one large program gets completed or delayed, the financials can suddenly look ugly.

That is exactly what happened after the completion of a large defence order in FY25.

4. Financials Overview

Since the latest heading is Quarterly Results, this is treated as a quarterly result set.

Annualised EPS is therefore Q4 FY26 EPS multiplied by 4.

Latest quarterly EPS is ₹2.83.

Annualised EPS becomes approximately ₹11.32.

At current price of ₹377, the annualised P/E works out to around 33.3 times.

Metric	Q4 FY26	Q4 FY25	Q3 FY26
Revenue	₹369 crore	₹428 crore	₹303 crore
EBITDA	₹43 crore	₹57 crore	₹28 crore
PAT	₹22 crore	₹31 crore	₹11 crore
EPS	₹2.83	₹3.91	₹1.41

The YoY comparison looks painful.

Revenue fell 13.8%, EBITDA fell 25%, and PAT fell 27.7%.

But sequentially, Q4 looked much better.

Revenue rose from ₹303 crore in Q3 to ₹369 crore in Q4. EBITDA rose from ₹28 crore to ₹43